RT Journal Article
SR Electronic
T1 Epidemiological, virological and serological investigation into a SARS-CoV-2 outbreak (Alpha variant) in a primary school: a prospective longitudinal study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.26.21265509
DO 10.1101/2021.10.26.21265509
A1 Lorthe, Elsa
A1 Bellon, Mathilde
A1 Michielin, Grégoire
A1 Berthelot, Julie
A1 Zaballa, María-Eugenia
A1 Pennacchio, Francesco
A1 Bekliz, Meriem
A1 Laubscher, Florian
A1 Arefi, Fatemeh
A1 Perez-Saez, Javier
A1 Azman, Andrew S
A1 L’Huillier, Arnaud G
A1 Posfay-Barbe, Klara M
A1 Kaiser, Laurent
A1 Guessous, Idris
A1 Maerkl, Sebastian
A1 Eckerle, Isabella
A1 Stringhini, Silvia
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/11/24/2021.10.26.21265509.abstract
AB We report a prospective epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak in a primary school, as part of a longitudinal, prospective, primary school-based surveillance study. It involved repeated testing of pupils and teachers and household members of participants who tested positive, with rapid antigen tests and/or RT-PCR (Day 0-2 and Day 5-7), serologies on dried capillary blood samples (Day 0-2 and Day 30), contact tracing interviews and SARS-CoV-2 whole genome sequencing. This SARS-CoV-2 outbreak caused by the Alpha variant involved 20 children aged 4 to 6 years from 4 classes, 2 teachers and a total of 4 household members. Infection attack rates were between 11.8 and 62.0% among pupils from the 4 classes, 22.2% among teachers and 0% among non-teaching staff. Secondary attack rate among household members was 15.4%. Symptoms were reported by 63% of infected children, 100% of teachers and 50% of household members. All analysed sequences but one showed 100% identity. Serological tests detected 8 seroconversions unidentified by SARS-CoV-2 virological tests. This study confirmed child-to-child and child-to-adult transmission of the infection. Effective measures to limit transmission in schools have the potential to reduce the overall community circulation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe SEROCoV-Schools study was supported by the Federal Office of Public Health, the Private Foundation of the Geneva University Hospitals, the Fondation des Grangettes and the Center for Emerging Viral Diseases, and a SNF NRP (National Research Program) 78 Covid-19 Grant 198412 (to S.J.M., I.E., and B.M.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of the Canton of Geneva (Project ID 2020-02957).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur data are accessible to researchers upon reasonable request for data sharing to Silvia Stringhini.